Ascendis Pharma AS (NASDAQ:ASND) saw unusually-strong trading volume on Wednesday . Approximately 71,377 shares traded hands during trading, an increase of 34% from the previous session’s volume of 53,084 shares.The stock last traded at $18.45 and had previously closed at $18.45.

A number of analysts have weighed in on ASND shares. Zacks Investment Research lowered Ascendis Pharma AS from a “hold” rating to a “sell” rating in a report on Tuesday, May 24th. Leerink Swann restated an “outperform” rating and set a $24.00 target price on shares of Ascendis Pharma AS in a report on Thursday, May 26th.

The firm’s market cap is $446.27 million. The stock has a 50-day moving average price of $14.32 and a 200 day moving average price of $15.81.

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.